# New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.

> PubMed lists PMID 20452924 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2010 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20452924-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20452924-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-20452924-liraglutide-v1.json
- Content SHA-256: `3f01cefefb49e66d625917b326e78b1eab35c4c8a9c16ffeb2d348b8409f4158`

## Claims and source pins

### Headline

New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA. ([`pubmed-observation-pmid-20452924-2015-11-19-f4f416513809`](#source-pubmed-observation-pmid-20452924-2015-11-19-f4f416513809))

### Summary

PubMed lists PMID 20452924 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2010 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20452924-2015-11-19-f4f416513809`](#source-pubmed-observation-pmid-20452924-2015-11-19-f4f416513809))

### Paragraph 1

PubMed lists PMID 20452924 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2010 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20452924-2015-11-19-f4f416513809`](#source-pubmed-observation-pmid-20452924-2015-11-19-f4f416513809))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20452924-2015-11-19-f4f416513809`](#source-pubmed-observation-pmid-20452924-2015-11-19-f4f416513809))

## Sources

<a id="source-pubmed-observation-pmid-20452924-2015-11-19-f4f416513809"></a>
- **New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA. · retained source version 1:2015-11-19:current:f4f416513809b8ff795e0180259b166a872da260c44318fe46bba825ad5eb5f3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20452924/) (`pubmed-observation-pmid-20452924-2015-11-19-f4f416513809`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-20452924-liraglutide-v1.json SHA-256: 3f01cefefb49e66d625917b326e78b1eab35c4c8a9c16ffeb2d348b8409f4158.